Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

J. Prochazkova, L. Slavik, J. Ulehlova, M. Prochazka

. 2015 ; 159 (2) : 192-196. [pub] 20141222

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, metaanalýza, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17006067

Grantová podpora
NT14394 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Tissue factor (TF) is a key element for normal gestation, especially in the first trimester. TF levels are hence raised in pregnancy, producing an adaptive hypercoagulable state. Potentiated hypercoagulability however, is associated with disorders of pregnancy such as pre-eclampsia but the results of TF and its inhibitor, tissue factor pathway inhibitor (TFPI), measurement, in pre eclampsic women are ambiguous and the data conflicting. This review covers the current knowledge status of the role of TF assessment in pregnancy with a focus on its diagnostic utility. METHODS: A review of the literature using the following key words: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia. RESULTS: The published literature shows raised and unchanged TF levels in various studies of pre-eclampsia along with equally conflicting data for TFPI. The various study designs and methods used in these studies makes valid comparison difficult. Meta analysis of 34 randomized trials showed that low-dose aspirin in early phases of gravidity (starting from the 16th week or earlier) significantly reduces the incidence of preeclampsia. CONCLUSIONS: Overall, the results of the literature search together with knowledge of the structure and biological effects of TF, suggest that measuring the level of plasma TF/TFPI is not ideal for determining the actual levels of TF in the uteroplacental circulation. The current view that endothelial dysfunction is the trigger for preeclampsia, suggests that aspirin may be an effective prophylaxis. Further research will be necessary: measuring the expression of tissue factor on monocytes using flowcytometry and comparing the development of this expression during normal pregnancy and pregnancy complicated by preeclampsia, for example. Another possibility is immunohistochemical determination of the level of TF expression directly in placental tissue.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17006067
003      
CZ-PrNML
005      
20181011120407.0
007      
ta
008      
170210s2015 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2014.061 $2 doi
035    __
$a (PubMed)25559093
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Procházková, Jana $u Department of Hemato-oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0067433
245    14
$a The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review / $c J. Prochazkova, L. Slavik, J. Ulehlova, M. Prochazka
520    9_
$a BACKGROUND: Tissue factor (TF) is a key element for normal gestation, especially in the first trimester. TF levels are hence raised in pregnancy, producing an adaptive hypercoagulable state. Potentiated hypercoagulability however, is associated with disorders of pregnancy such as pre-eclampsia but the results of TF and its inhibitor, tissue factor pathway inhibitor (TFPI), measurement, in pre eclampsic women are ambiguous and the data conflicting. This review covers the current knowledge status of the role of TF assessment in pregnancy with a focus on its diagnostic utility. METHODS: A review of the literature using the following key words: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia. RESULTS: The published literature shows raised and unchanged TF levels in various studies of pre-eclampsia along with equally conflicting data for TFPI. The various study designs and methods used in these studies makes valid comparison difficult. Meta analysis of 34 randomized trials showed that low-dose aspirin in early phases of gravidity (starting from the 16th week or earlier) significantly reduces the incidence of preeclampsia. CONCLUSIONS: Overall, the results of the literature search together with knowledge of the structure and biological effects of TF, suggest that measuring the level of plasma TF/TFPI is not ideal for determining the actual levels of TF in the uteroplacental circulation. The current view that endothelial dysfunction is the trigger for preeclampsia, suggests that aspirin may be an effective prophylaxis. Further research will be necessary: measuring the expression of tissue factor on monocytes using flowcytometry and comparing the development of this expression during normal pregnancy and pregnancy complicated by preeclampsia, for example. Another possibility is immunohistochemical determination of the level of TF expression directly in placental tissue.
650    _2
$a hemokoagulace $x fyziologie $7 D001777
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a preeklampsie $x krev $x etiologie $7 D011225
650    _2
$a těhotenství $7 D011247
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a tkáňový faktor $x fyziologie $7 D013925
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Slavík, Luděk $u Department of Hemato-oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0081908
700    1_
$a Úlehlová, Jana $u Department of Hemato-oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0117725
700    1_
$a Procházka, Martin, $u Department of Obstetrics and Gynecology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc; Department of Midwifery, Faculty of Health Sciences, Palacky University Olomouc $d 1970- $7 xx0019288
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 159, č. 2 (2015), s. 192-196
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170210 $b ABA008
991    __
$a 20181011120858 $b ABA008
999    __
$a ok $b bmc $g 1192592 $s 966714
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 159 $c 2 $d 192-196 $e 20141222 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
GRA    __
$a NT14394 $p MZ0
LZP    __
$b NLK118 $a Pubmed-20170210

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...